Status:
COMPLETED
Exploring the Role of the GABAergic Modulation in Pain Transmission in Human
Lead Sponsor:
Jules Desmeules
Conditions:
Neuropathic Pain
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
Neuropathic pain affects about 7% of the general population in European countries. Meta-analyses indicate that only a minority of neuropathic pain patients has adequate response to drug therapy and ma...
Eligibility Criteria
Inclusion
- Male subject, age between 18 and 50 years old
- Caucasian
- Type 3 skin phototype (white skin that can tan gradually and burns moderately)
- Non smoker or moderate smoker (\< 10 cigarettes/day)
- No clinically abnormal findings on history and/or on physical examination
- Positive minimal erythema dose (MED) determination
Exclusion
- Any active significant illness
- Current or past history of drug and alcohol abuse or current intake of more than 3 glasses of alcohol a day or more than 21 glasses of alcohol per week
- Psychotropic drug intake during the last month
- Sun allergy or any skin disease
- Any regular drug intake
- CYP2C19 poor metabolizer (phenotype)
Key Trial Info
Start Date :
March 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2018
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03375034
Start Date
March 30 2017
End Date
January 31 2018
Last Update
April 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UGeneva
Geneva, Switzerland, 1211